Korro Bio (KRRO) Restructuring Costs (2025)
Korro Bio's (KRRO) quarterly Restructuring Costs came in at $1.2 million in Q2 2025.
Powered by 
Analysis
Korro Bio (KRRO) Restructuring Costs (2025) Analysis & Trends
Korro Bio (KRRO) has reported Restructuring Costs for 1 consecutive years, with $1.2 million the latest figure, recorded in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn |
| 10 | Korro Bio | 225.43 Mn | 110.39 Mn | - |